Physician profile
Tess Lee
NPI 1396230926
$2,317.70
in general payments reported to CMS, 2019-2025
22 companies · $515 in 2025
The $515 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $226 · 2023: $900 · 2024: $413 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $437.34 | 2021-2025 | Yeztugo |
| Lilly USA, LLC | $319.82 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $298.06 | 2022-2025 | |
| Pfizer INC. | $278.19 | 2021-2025 | |
| Exact Sciences Corporation | $145.04 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $126.50 | 2021-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $125.00 | 2023 | |
| Inspire Medical Systems, INC. | $104.28 | 2023-2025 | Inspire |
| Viiv Healthcare Company | $68.08 | 2023-2024 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.23 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $53.20 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $52.08 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $42.53 | 2021 | |
| Phadia US INC. | $30.62 | 2023-2024 | Immunocap |
| Aerin Medical INC. | $27.51 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.78 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $24.61 | 2024 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $22.10 | 2025 | Strensiq |
| Merck Sharp & Dohme LLC | $20.03 | 2025 | Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $18.28 | 2023 | Shingrix |
| Corcept Therapeutics | $18.20 | 2024 | Korlym |
| Tms Neurohealth Centers INC. | $16.22 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tess Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.